Corporación Inmobiliaria Vesta, S.A.B. de C.V. (VTMX)

Sage Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Sage Therapeutics stock have a consensus rating of "Sell" and an average price target of $29.5, which forecasts a 4.17% increase in the stock price over the next year. The lowest target is $21 and the highest is $38.

Price Target: $29.50 (+4.17%)

Analyst Consensus: Sell

Target	Low	Average	Median	High
Price	$21	$29.5	$38	$38
Change	-25.85%	+4.17%	+34.18%	+34.18%

Analyst Ratings

The average analyst rating for Sage Therapeutics stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	0	0	0	0	0	0
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Pablo Monsivais Barclays	Barclays	Buy Maintains $37 → $38	Buy	Maintains	$37 → $38	+34.18%	Jul 29, 2025
Pablo Monsivais Barclays	Barclays	Buy Maintains $34 → $37	Buy	Maintains	$34 → $37	+30.65%	Jun 23, 2025
Jorel Guilloty Goldman Sachs	Goldman Sachs	Hold → Strong Sell Downgrades $31 → $21	Hold → Strong Sell	Downgrades	$31 → $21	-25.85%	Mar 25, 2025
Pablo Monsivais Barclays	Barclays	Buy Maintains $35 → $34	Buy	Maintains	$35 → $34	+20.06%	Mar 6, 2025
Pablo Monsivais Barclays	Barclays	Buy Maintains $38 → $35	Buy	Maintains	$38 → $35	+23.59%	Nov 27, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

291.11M

Increased by 15.37%

from 252.33M

Revenue Next Year

323.20M

Increased by 11.02%

from 291.11M

EPS This Year

0.18

Decreased by -28.49%

from 0.25

EPS Next Year

0.22

Increased by 20.71%

from 0.18

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	149.86M	160.79M	178.03M	214.47M	252.33M	291.11M	323.20M	335.58M
Revenue Growth	3.80%	7.29%	10.72%	20.47%	17.65%	15.37%	11.02%	3.83%
EPS	0.12	0.26	0.35	0.41	0.25	0.18	0.22	0.16
EPS Growth	-49.09%	125.88%	33.12%	17.36%	-38.59%	-28.49%	20.71%	-24.51%
Forward PE	-	-	-	-	-	156.59	129.72	171.84
No. Analysts	-	-	-	-	-	11	11	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028
High	354.4M	388.9M	361.2M
Avg	291.1M	323.2M	335.6M
Low	247.9M	282.6M	304.0M

Revenue Growth

Revenue Growth	2025	2026	2027	2028
High	40.4%	33.6%	11.8%
Avg	15.4%	11.0%	3.8%
Low	-1.7%	-2.9%	-5.9%

EPS Forecast

EPS	2025	2026	2027	2028
High	0.23	0.29	0.17
Avg	0.18	0.22	0.16
Low	0.14	0.15	0.16

EPS Growth

EPS Growth	2025	2026	2027	2028
High	-8.7%	62.6%	-23.0%
Avg	-28.5%	20.7%	-24.5%
Low	-45.7%	-18.7%	-28.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.